Home › SEC Filings › Current Report (8-K)
Current Report (8-K)
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| GYRE | 8-K | neutral | 4/10 | Gyre Therapeutics filed an 8-K furnishing an updated corporate investor presentation. The presentation highlights the co | Sep 1, 2026 |
| CUB | 8-K | bearish | 6/10 | Lionheart Holdings (CUB), a SPAC, disclosed that its proposed business combination with KEO Energy (Maha Energy Indiana | Sep 1, 2026 |
| CNO | 8-K | neutral | 3/10 | CNO held a routine investor briefing on September 1, 2026, focused on its Worksite Division and Medicare business. The p | Sep 1, 2026 |
| GGG | 8-K | bullish | 6/10 | Graco Inc. announced the completion of its previously announced acquisition of Valco Melton for $447 million in cash. Th | Sep 1, 2026 |
| ZEOX | 8-K | neutral | 2/10 | ZEO filed an 8-K announcing the faculty and guest speaker lineup for its inaugural ZEO Xperience, a three-day regenerati | Sep 1, 2026 |
| ALMS | 8-K | mixed | 6/10 | Alumis reported topline results from the Phase 2b LUMUS trial of envudeucitinib in moderate-to-severe SLE. The trial did | Sep 1, 2026 |
| NCSM | 8-K | bullish | 8/10 | NCS Multistage Holdings, Inc. has been acquired by Weatherford International plc in a stock-and-cash merger. Each NCSM s | Sep 1, 2026 |
| COPR | 8-K | neutral | 5/10 | Idaho Copper provided a Q2 2026 corporate update highlighting its uplisting to the NYSE American, completion of an ~$18M | Sep 1, 2026 |
| WFRD | 8-K | neutral | 2/10 | Weatherford International filed a prospectus supplement for the resale of up to 357,159 ordinary shares by a selling sha | Sep 1, 2026 |
| PFSA | 8-K | bearish | 6/10 | Profusa issued a $329,670.33 senior secured convertible promissory note to Ascent Partners Fund LLC for $300,000 in cash | Sep 1, 2026 |
| CPK | 8-K | bullish | 7/10 | Chesapeake Utilities (CPK) finalized a joint venture with NextEra Energy Resources (NEER) for the Florida Energy Pathway | Sep 1, 2026 |
| ACET | 8-K | neutral | 5/10 | Adicet Bio announced completion of the last patient visit for the planned Phase 1 analysis of prula-cel in SLE with or w | Sep 1, 2026 |
| IVVD | 8-K | neutral | 6/10 | Invivyd appointed Chairman Marc Elia as CEO, replacing the CFO who had been serving as principal executive officer. The | Sep 1, 2026 |
| MSTR | 8-K | neutral | 3/10 | Strategy Inc declared routine quarterly and semi-monthly cash dividends on its preferred stock series (STRF, STRE, STRK, | Sep 1, 2026 |
| YUMC | 8-K | neutral | 2/10 | Yum China filed an 8-K on September 1, 2026, solely to disclose that it issued its interim report for the six months end | Sep 1, 2026 |
| HUM | 8-K | neutral | 3/10 | Humana filed an 8-K to reaffirm its FY 2026 guidance of at least $6.52 GAAP EPS and at least $9.00 adjusted EPS, consist | Sep 1, 2026 |
| FRVO | 8-K | bullish | 7/10 | Fervo Energy signed a 396 MW power purchase agreement (PPA) with Google, the world's largest enhanced geothermal PPA, fo | Sep 1, 2026 |
| INDP | 8-K | bearish | 5/10 | Indaptus Therapeutics entered into an amended and restated at-the-market offering agreement with H.C. Wainwright, enabli | Sep 1, 2026 |
| KDP | 8-K | bullish | 6/10 | KDP announced a definitive agreement to sell its entire minority equity stake in Chobani back to Chobani for $800 millio | Sep 1, 2026 |
| YEXT | 8-K | mixed | 6/10 | Yext reported Q2 FY27 revenue of $111.1M (-2% YoY), a GAAP EPS of $0.13, and a non-GAAP EPS of $0.21. While total revenu | Sep 1, 2026 |
| IRHO | 425, 8-K | neutral | 4/10 | Iron Horse Acquisition II Corp. (IRHO) and its merger target Electra AI announced that Mooving, an Indian smart battery- | Sep 1, 2026 |
| XXII | 8-K | neutral | 3/10 | 22nd Century Group issued a mid-year shareholder letter highlighting operational progress: VLN cigarette same-store sale | Sep 1, 2026 |
| CDT | 8-K | bearish | 6/10 | CDT Equity Inc. appointed James Bligh as CEO, replacing Dr. Andrew Regan who resigned immediately. Bligh, who also remai | Sep 1, 2026 |
| MIRA | 8-K | neutral | 4/10 | MIRA Pharmaceuticals announced positive results from 7-day dose-range finding toxicology and toxicokinetic studies of MI | Sep 1, 2026 |
| FIGR | 8-K | mixed | 6/10 | Figure Technology Solutions completed its $590M acquisition of Kiavi, funded by $600M in 8.5% senior notes due 2031. The | Sep 1, 2026 |
| UPB | 8-K | bullish | 7/10 | Upstream Bio announced pivotal Phase 3 development plans for verekitug in severe asthma and CRSwNP following productive | Sep 1, 2026 |
| LIDR | 8-K | bullish | 5/10 | AEye announced that its Apollo lidar has been selected by Lunar Outpost for integration onto the Pegasus Lunar Terrain V | Sep 1, 2026 |
| NVCR | 8-K | neutral | 3/10 | NovoCure disclosed a cybersecurity incident from mid-August 2026 involving unauthorized access to some information syste | Sep 1, 2026 |
| BTAI | 8-K | bearish | 9/10 | BioXcel Therapeutics filed for Chapter 11 bankruptcy on August 27, 2026, and this 8-K reports two terminal events: (1) e | Sep 1, 2026 |
| AITX | 8-K | neutral | 2/10 | AITX filed an 8-K announcing its subsidiary RAD will participate in GSX 2026 (Sept 14-16) with an education session and | Sep 1, 2026 |